What is Agena Bioscience?
Founded in 2014, Agena Bioscience specializes in the development, manufacturing, and supply of advanced genetic analysis systems and high-performance reagents. The company is best known for its proprietary MassARRAY System, a versatile platform that enables high-throughput, cost-effective genomic analysis. By providing scalable solutions for clinical and research applications, Agena Bioscience has established itself as a critical infrastructure provider for laboratories focused on precision medicine, oncology, and infectious disease testing. Its market position is defined by a commitment to delivering actionable genomic insights through streamlined workflows and reliable diagnostic technology.
How much funding has Agena Bioscience raised?
Agena Bioscience has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Agena Bioscience
PPP
Public-Private Partnership
What's next for Agena Bioscience?
With this major enterprise-level funding, Agena Bioscience is expected to prioritize the scaling of its commercial operations and the enhancement of its R&D pipeline. The strategic allocation of these funds will likely focus on expanding the utility of the MassARRAY platform, potentially targeting new clinical diagnostic applications and international market penetration. As the demand for rapid, accurate genetic testing continues to rise, the company is poised to leverage its technological edge to capture additional market share. Future growth trajectories will likely involve deepening partnerships with clinical research organizations and diagnostic laboratories, ensuring that Agena Bioscience remains at the forefront of the molecular diagnostics evolution.
See full Agena Bioscience company page
